Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00451178 · ClinicalTrials.gov registry record · Phase 2
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT00451178 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 101 participants.
The verdict
NCT00451178, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
To compare R-CHOP plus enzastaurin versus R-CHOP for progression-free survival (PFS) time measured in participants with intermediate and/or high risk for diffuse large B-cell lymphoma (DLBCL) receiving first-line treatment.
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG rituximab
- DRUG vincristine
- DRUG enzastaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2007-05 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00451178
The ClinicalTrials.gov registry entry for NCT00451178 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00451178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00451178 about?
NCT00451178 is a clinical study titled "A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only". To compare R-CHOP plus enzastaurin versus R-CHOP for progression-free survival (PFS) time measured in participants with intermediate and/or high risk for diffuse large B-cell lymphoma (DLBCL) receiving first-line treatment.
What is the current status of trial NCT00451178?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2007-05. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00451178?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin (DRUG), rituximab (DRUG), vincristine (DRUG), enzastaurin (DRUG).
Who is sponsoring clinical trial NCT00451178?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.